Friday October 2, 2020
In todays report:
click here for the link to the video on youtube
D.C. Expands Medical Marijuana Deliveries Amid Coronavirus And Shifts Regulatory Control To Alcohol Agency
Washington, D.C. is continuing to expand access to medical marijuana amid the coronavirus pandemic, with regulators announcing on Thursday that delivery services and registration card expiration dates will be extended.
Notably, as of October 1, the district’s Alcoholic Beverage Regulation Administration (ABRA) is now responsible for overseeing the medical cannabis program, taking over for the Department of Health
But for now it remains the case that a c
ongressional rider blocks D.C. from using its own local tax dollars to set up a legal adult-use cannabis market. In the meantime, regulators are focused on improving patient access while mitigating the spread of COVID-19.
of District residents.”
Further, patients and caregivers whose medical cannabis registrations expired on or after March 11 will be extended until 45 days after the city’s COVID-19 public health emergency concludes.
And, in an attempt to prevent backlogs and meet patient demand, ABRA also adopted a rule that allows people to work at a cultivation facility, dispensary or testing lab for 45 days while their criminal background checks are being processed.
a legal adult-use market in the district. D.C. voters legalized the low-level possession and cultivation of marijuana for adult use in 2014
annually renewed.
Rep. Eleanor Holmes Norton (D-DC) has been a particularly vocal critic of the rider,
Mayor Muriel Bowser (D) unveiled a legalization bill last year, and part of it calls for ABRA to regulate the legal industry and for the agency to be renamed the Alcoholic Beverage and Cannabis Administration. Now that ABRA is in control of the medical cannabis program
Scientists Demand DEA Reconsider Marijuana’s Federal Status In New Court Briefing
Scientists And Veterans File Lawsuit Challenging DEA’s Marijuana Rescheduling Denials
requests.
The Scottsdale Research Institute (SRI) filed suit last week in the U.S. Ninth Circuit Court of Appeals, asking for a review of DEA’s scheduling determinations in 2020, 2016 and 1992. In all cases, the agency denied the petitions, citing statutory obligations to maintain the status of cannabis as a Schedule I drug under the Controlled Substances Act.
Lawyers representing a group of scientists and military veterans filed a comprehensive brief in federal court this week, outlining their case challenging decisions about the classification of marijuana made by the Drug Enforcement Administration (DEA).
The plaintiffs make a second legal argument that’s more nuanced. They say that DEA’s insistence that cannabis must be placed in either Schedule I or Schedule II is unconstitutional because it “delegates legislative power twice: first to a non-governmental entity and second to the Attorney General.” The “non-governmental entity” is a reference to international treaties that the agency has cited as restricting its authority to reschedule cannabis
cannabis.
In order to provide relief, the attorneys want the court to mandate that DEA take three steps: First, it should initiate a rulemaking process on rescheduling. Next, it should complete the rulemaking within a year of the court’s order. Finally, it should make sure that any scheduling decision is consistent with a statute that the attorneys say prevents DEA from “denying that marijuana has a currently accepted medical use in the face of widespread State acceptance.”
Matt Zorn and Shane Pennington, attorneys for the plaintiffs, told Marijuana Moment that getting DEA to initiate formal rulemaking would open the floodgates, enabling experts and stakeholders to lay out the abundance of scientific and legal literature that contradicts the rationale behind placing cannabis in Schedule I.
.
The plaintiffs were also successful in forcing DEA to issue an update on the status of applications to become federally authorized cannabis manufacturers for research purposes and then got the Justice Department to hand over a “secret” memo that DEA allegedly used to justify a delay in deciding on those proposals.
Body Shop launches three CBD skin-care products in UK, US
and in select states.
The Body Shop said on its U.S. website that, “due to individual state restriction,” CBD is not available for sale in:
Alaska.
Arizona.
Delaware.
Hawaii.
Idaho.
Louisiana.
Mississippi.
Ohio.
for comment.
The company also carries a separate line of hempseed oil bath and skin-care products.
L’Oréal sold The Body Shop to Brazilian cosmetics maker Natura Cosméticos in 2017.
United Kingdom, has launched three CBD skin-care products for retail sales in the U.K. and the United States.
The collection launched on Sep. 22 in the U.K. and includes a face oil, a moisturizer and a cleansing mask.
https://hempindustrydaily.com/the-body-shop-launches-three-cbd-skincare-products-in-the-u-k-u-s/